On June 23, Qingsong Health rose 13.64% in regular trading, reaching HK$16.22 per share, with turnover of approximately HK$52.89 million.

On the news front, the company recently released multiple positive developments in rapid succession. Qingsong Health signed a strategic cooperation agreement with Shanghai Pharma Holdings (Hunan) Biological Products, with both parties leveraging the proprietary evidence-based medical AI agent ZhengYuanFang to build a rare disease intelligent screening and full-cycle health management system. Simultaneously, the company entered into a three-year strategic MOU with Basel Medical Group to jointly expand into the Southeast Asian market.

Additionally, controlling shareholder Yang Yin voluntarily extended her lock-up period to January 1, 2027, while the board resolved to repurchase up to HK$100 million worth of shares from the open market. These measures effectively alleviated prior market concerns over imminent lock-up expiry selling pressure, with approximately 43 million shares previously expected to become tradable by end of June representing over 20% of total share capital.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)